scholarly journals Challenges for the Development of Extracellular Vesicle-Based Nucleic Acid Medicines

Cancers ◽  
2021 ◽  
Vol 13 (23) ◽  
pp. 6137
Author(s):  
Naoya Kuriyama ◽  
Yusuke Yoshioka ◽  
Shinsuke Kikuchi ◽  
Akihiko Okamura ◽  
Nobuyoshi Azuma ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Extracellular Vesicle ◽  
Parent Cell ◽  
Therapeutic Effects ◽  
Delivery Methods ◽  
Genetic Changes ◽  
Passive Targeting ◽  
Target Organs ◽  
Genetically Engineer ◽  
Nucleic Acid Drug

Nucleic acid drugs, such as siRNAs, antisense oligonucleotides, and miRNAs, exert their therapeutic effects by causing genetic changes in cells. However, there are various limitations in their delivery to target organs and cells, making their application to cancer treatment difficult. Extracellular vesicles (EVs) are lipid bilayer particles that are released from most cells, are stable in the blood, and have low immunogenicity. Methods using EVs to deliver nucleic acid drugs to target organs are rapidly being developed that take advantage of these properties. There are two main methods for loading nucleic acid drugs into EVs. One is to genetically engineer the parent cell and load the target gene into the EV, and the other is to isolate EVs and then load them with the nucleic acid drug. Target organ delivery methods include passive targeting using the enhanced permeation and retention effect of EVs and active targeting in which EVs are modified with antibodies, peptides, or aptamers to enhance their accumulation in tumors. In this review, we summarize the advantages of EVs as a drug delivery system for nucleic acid drugs, the methods of loading nucleic acid drugs into EVs, and the targeting of EVs to target organs.

scholarly journals Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro

Viruses ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 650
Author(s):  
Gunsup Lee ◽  
Shailesh Budhathoki ◽  
Geum-Young Lee ◽  
Kwang-ji Oh ◽  
Yeon Kyoung Ham ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Antiviral Activity ◽  
Broad Spectrum ◽  
Recombinant Antibody ◽  
Therapeutic Effects ◽  
Single Chain Variable Fragment ◽  
Single Chain ◽  
Diarrhea Virus ◽  
3D8 Scfv

The virus behind the current pandemic, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the etiology of novel coronavirus disease (COVID-19) and poses a critical public health threat worldwide. Effective therapeutics and vaccines against multiple coronaviruses remain unavailable. Single-chain variable fragment (scFv), a recombinant antibody, exhibits broad-spectrum antiviral activity against DNA and RNA viruses owing to its nucleic acid-hydrolyzing property. The antiviral activity of 3D8 scFv against SARS-CoV-2 and other coronaviruses was evaluated in Vero E6 cell cultures. Viral growth was quantified with quantitative RT-qPCR and plaque assay. The nucleic acid-hydrolyzing activity of 3D8 was assessed through abzyme assays of in vitro viral transcripts and cell viability was determined by MTT assay. We found that 3D8 inhibited the replication of SARS-CoV-2, human coronavirus OC43 (HCoV-OC43), and porcine epidemic diarrhea virus (PEDV). Our results revealed the prophylactic and therapeutic effects of 3D8 scFv against SARS-CoV-2 in Vero E6 cells. Immunoblot and plaque assays showed the reduction of coronavirus nucleoproteins and infectious particles, respectively, in 3D8 scFv-treated cells. These data demonstrate the broad-spectrum antiviral activity of 3D8 against SARS-CoV-2 and other coronaviruses. Thus, it could be considered a potential antiviral countermeasure against SARS-CoV-2 and zoonotic coronaviruses.

Proteomic Profile of Urinary Extracellular Vesicles Identifies AGP1 as a Potential Biomarker of Primary Aldosteronism

Endocrinology ◽  
2021 ◽  
Vol 162 (4) ◽  
Author(s):  
Eric R Barros ◽  
Juan Pablo Rigalli ◽  
Alejandra Tapia-Castillo ◽  
Andrea Vecchiola ◽  
Morag J Young ◽  
...  
Keyword(s):  
Extracellular Vesicles ◽  
Primary Aldosteronism ◽  
Proteomic Analysis ◽  
Characteristic Curve ◽  
Area Under The Curve ◽  
Extracellular Vesicle ◽  
Parent Cell ◽  
Spot Urine ◽  
Potential Biomarker ◽  
Aldosterone To Renin Ratio

Abstract Context Primary aldosteronism (PA) represents 6% to 10% of all essential hypertension patients and is diagnosed using the aldosterone-to-renin ratio (ARR) and confirmatory studies. The complexity of PA diagnosis encourages the identification of novel PA biomarkers. Urinary extracellular vesicles (uEVs) are a potential source of biomarkers, considering that their cargo reflects the content of the parent cell. Objective We aimed to evaluate the proteome of uEVs from PA patients and identify potential biomarker candidates for PA. Methods Second morning spot urine was collected from healthy controls (n = 8) and PA patients (n = 7). The uEVs were isolated by ultracentrifugation and characterized. Proteomic analysis on uEVs was performed using LC-MS Orbitrap. Results Isolated uEVs carried extracellular vesicle markers, showed a round shape and sizes between 50 and 150 nm. The concentration of uEVs showed a direct correlation with urinary creatinine (r = 0.6357; P = 0.0128). The uEV size mean (167 ± 6 vs 183 ± 4nm) and mode (137 ± 7 vs 171 ± 11nm) was significantly smaller in PA patients than in control subjects, but similar in concentration. Proteomic analysis of uEVs from PA patients identified an upregulation of alpha-1-acid glycoprotein 1 (AGP1) in PA uEVs, which was confirmed using immunoblot. A receiver operating characteristic curve analysis showed an area under the curve of 0.92 (0.82 to 1; P = 0.0055). Conclusion Proteomic and further immunoblot analyses of uEVs highlights AGP1 as potential biomarker for PA.

scholarly journals Genome-wide interrogation of extracellular vesicle biology using barcoded miRNAs

eLife ◽  
2018 ◽  
Vol 7 ◽  
Author(s):  
Albert Lu ◽  
Paulina Wawro ◽  
David W Morgens ◽  
Fernando Portela ◽  
Michael C Bassik ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Molecular Mechanisms ◽  
Membrane Vesicles ◽  
Extracellular Vesicle ◽  
Biologically Active ◽  
Vesicle Release ◽  
Guide Rnas ◽  
Disease States ◽  
Genome Wide ◽  
First Time

Extracellular vesicles mediate transfer of biologically active molecules between neighboring or distant cells, and these vesicles may play important roles in normal physiology and the pathogenesis of multiple disease states including cancer. However, the underlying molecular mechanisms of their biogenesis and release remain unknown. We designed artificially barcoded, exosomal microRNAs (bEXOmiRs) to monitor extracellular vesicle release quantitatively using deep sequencing. We then expressed distinct pairs of CRISPR guide RNAs and bEXOmiRs, enabling identification of genes influencing bEXOmiR secretion from Cas9-edited cells. This approach uncovered genes with unrecognized roles in multivesicular endosome exocytosis, including critical roles for Wnt signaling in extracellular vesicle release regulation. Coupling bEXOmiR reporter analysis with CRISPR-Cas9 screening provides a powerful and unbiased means to study extracellular vesicle biology and for the first time, to associate a nucleic acid tag with individual membrane vesicles.

scholarly journals Cover Picture: Nanopore-Based Analysis of Chemically Modified DNA and Nucleic Acid Drug Targets (Isr. J. Chem. 6-7/2013)

2013 ◽  
Vol 53 (6-7) ◽  
pp. 317-317
Author(s):  
Joseph Larkin ◽  
Spencer Carson ◽  
Daniel H. Stoloff ◽  
Meni Wanunu
Keyword(s):  
Nucleic Acid ◽  
Drug Targets ◽  
Chemically Modified ◽  
Modified Dna ◽  
Nucleic Acid Drug

DAPI - pUC8 complex: A tool to investigate biological effects of nucleic acid-drug interaction

1987 ◽  
Vol 145 (1) ◽  
pp. 40-45 ◽  
Author(s):  
Giorgio Palu' ◽  
Sebastiano Valisena ◽  
Maria Luisa Barcellona ◽  
Lanfranco Masotti ◽  
Giovanni A. Meloni
Keyword(s):  
Drug Interaction ◽  
Nucleic Acid ◽  
Biological Effects ◽  
Nucleic Acid Drug

scholarly journals Measurement and standardization challenges for extracellular vesicle therapeutic delivery vectors

Nanomedicine ◽  
2020 ◽  
Vol 15 (22) ◽  
pp. 2149-2170
Author(s):  
Bryant C Nelson ◽  
Samantha Maragh ◽  
Ionita C Ghiran ◽  
Jennifer C Jones ◽  
Paul C DeRose ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Nucleic Acid ◽  
Lipid Bilayer ◽  
Cell Types ◽  
Extracellular Vesicle ◽  
Clinical Therapeutics ◽  
Measurement Systems ◽  
Therapeutic Delivery ◽  
Efficient Delivery ◽  
Standardized Measurement

Extracellular vesicles (EVs), such as exosomes and microvesicles, are nonreplicating lipid bilayer particles shed by most cell types which have the potential to revolutionize the development and efficient delivery of clinical therapeutics. This article provides an introduction to the landscape of EV-based vectors under development for the delivery of protein- and nucleic acid-based therapeutics. We highlight some of the most pressing measurement and standardization challenges that limit the translation of EVs to the clinic. Current challenges limiting development of EVs for drug delivery are the lack of: standardized cell-based platforms for the production of EV-based therapeutics; EV reference materials that allow researchers/manufacturers to validate EV measurements and standardized measurement systems for determining the molecular composition of EVs.

scholarly journals MetastamiRs: A promising choice for antihepatocellular carcinoma nucleic acid drug development

2016 ◽  
Vol 47 (1) ◽  
pp. 80-94 ◽  
Author(s):  
Liangcai Wu ◽  
Xue Bai ◽  
Yuan Xie ◽  
Zhen Yang ◽  
Xiaobo Yang ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Drug Development ◽  
Nucleic Acid Drug
Sign in / Sign up

Export Citation Format

Share Document